|
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development
HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery Life Sciences (Discovery), a provider of biospecimens and biomarker specialty lab services, and Mindpeak, a leading company in AI-powered digital pathology, today announced a partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.
The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions.
The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyze IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy.
Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training program established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 EU countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumor quantification, and detailed tumor microenvironment characterization across various therapeutic areas.
"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies."
The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development.
"This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO of Mindpeak. Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026. Attendees can join a flash talk at the Discovery Life Sciences exhibit from April 17-22 at the San Diego Convention Center in San Diego, California. Contact info@dls.com for more information.
About Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives.
Visit www.dls.com and follow us on LinkedIn for more information.
About Mindpeak
Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.
For more information, visit www.mindpeak.ai or follow us on LinkedIn.
Discovery Life Sciences Media
Todd Poley
Chief Marketing Officer
+1 256 505 1578
todd.poley@dls.com
Mindpeak Media
Tanya von Ahlefeldt
MD Health – on behalf of Mindpeak
+44 (0)7590 754906
mindpeak@mdhealthcomms.com
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development
HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery Life Sciences (Discovery), a provider of biospecimens and biomarker specialty lab services, and Mindpeak, a leading company in AI-powered digital pathology, today announced a partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.
The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions.
The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyze IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy.
Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training program established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 EU countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumor quantification, and detailed tumor microenvironment characterization across various therapeutic areas.
"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies."
The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development.
"This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO of Mindpeak. Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026. Attendees can join a flash talk at the Discovery Life Sciences exhibit from April 17-22 at the San Diego Convention Center in San Diego, California. Contact info@dls.com for more information.
About Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives.
Visit www.dls.com and follow us on LinkedIn for more information.
About Mindpeak
Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.
For more information, visit www.mindpeak.ai or follow us on LinkedIn.
Discovery Life Sciences Media
Todd Poley
Chief Marketing Officer
+1 256 505 1578
todd.poley@dls.com
Mindpeak Media
Tanya von Ahlefeldt
MD Health – on behalf of Mindpeak
+44 (0)7590 754906
mindpeak@mdhealthcomms.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
Empowered by 90° alignment, real-time depth sensing with 0.1 mm accuracy, and Adaptive Torque Intelligence, the ST3 redefines precision for drilling and controlled tapping.
NEW YORK, March 24, 2026 /PRNewswire/ -- SPESYN today announced the launch of SPESYN Tool 3, a smart cordless power tool designed to make precision drilling, tapping and screw-driving more consistent. A Kickstarter campaign will go live on March 24, giving makers, DIYers and professional users early access to this new tool.
Drilling straight, controlling depth in blind holes and cutting clean internal threads are common workshop tasks, but achieving consistent results with handheld tools is difficult. Users often need large drill presses or separate tapping tools for accuracy, which can slow down smaller jobs and require different setups.
While traditional drills offer basic functionality, the SPESYN ST3 is engineered with specialized control for drilling, screw-driving and a dedicated tapping mode. It achieves 90° alignment through a precision mechanical guide, while integrated sensors and an LCD display provide real-time depth readings with ±0.1 mm accuracy.
Founded by robotics engineers, the team behind SPESYN spends much of its time machining parts and building hardware prototypes. "Many makers and builders rely on large machines or multiple tools to achieve precise results," said Sam Tsai. "SPESYN ST3 was designed to bring that level of precision into a compact handheld tool for everyone from hobbyists and homeowners to professionals."
The SPESYN Tool 3 Kickstarter campaign will launch at 9:00 AM EST on March 24, offering early supporters exclusive rewards and the opportunity to be among the first to get their hands on the tool. Visit the website for details and early-bird pricing: https://www.kickstarter.com/projects/spesynlab/spesyn-tool-3-the-ultimate-smart-power-tool?ref=14mqvw
Key Features of SPESYN ST3
All-in-One Precision Tool
Integrates drilling, screw-driving and a dedicated tapping mode, with task-specific control and optimized output for more consistent results every time.
90° Precision Alignment
A detachable Front Guide Module (FGM) and dual guide rails help keep the bit perpendicular to the work surface, even on smooth materials such as tile or glass.
±0.1 mm Depth Accuracy
A built-in LCD displays drilling depth in real time with one-touch zeroing, helping users drill and tap blind holes accurately.
Adaptive Torque Intelligence (ATI)
The ST3 features a robust brushless motor and an electronic clutch powered by Adaptive Torque Intelligence (ATI). By sampling current up to 25,000 times per second, the system dynamically optimizes power delivery for any task - ensuring stable performance while providing the surgical precision to prevent material damage without sacrificing raw strength.
Modular and Expandable Design
An interchangeable Front Guide interface allows the ST3 to adapt to various bit lengths and drilling angles via specialized modules. In addition to official options like integrated dust collection, the system's open architecture supports custom-built jigs for highly specialized applications.
Portable Design and Material Versatility
The ST3 reaches a 20% to 80% charge in under 30 minutes (65W fast charging). From raw power for hardened metal to crack-free precision for glass and tile, the ST3 delivers professional mastery in a compact form.
About SPESYN
SPESYN is a hardware company focused on developing precision tools that make complex tasks easier and more reliable. Founded by engineers with backgrounds in robotics and hardware development, the company designs products that combine mechanical accuracy with intelligent control. SPESYN's tools are built to help makers, engineers and DIY builders work with greater precision, efficiency and confidence across a wide range of materials and applications. Learn more at www.spesyn.com.
Press Inquiries:
Sam Tsai
Head of Marketing, SPESYN
marketing@spesyn.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
SPESYN Launches ST3 on Kickstarter, Bringing Drill-Press Precision to a Handheld Power Tool
